StockDrifts LogoStockDrifts

PFM Health Sciences 13F Portfolio ยท Christopher James

Portfolio Manager
Christopher James
Performance
+19.78% (2026 Q2)
AUM (13F)
$1.17B
# of Holdings
96
Performance Rank
Allocation (Top 20)
47.53%
Latest filing
Q2 2026

Pfm Health Sciences LP Holdings Map

Top 50 Pfm Health Sciences LP Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
AXSM
AXSOME THERAPEUTICS INC.
4.67%219.6K$53.8M
-16.92%(-44.71K)
2025-Q2: 483.1K shares2025-Q3: 530.3K shares2025-Q4: 251.6K shares2026-Q1: 264.3K shares2026-Q2: 219.6K shares
$62.04(+244.41%)
2026-06-30
LLY
ELI LILLY & CO
4.09%39.3K$47.1M
-40.30%(-26.50K)
2025-Q2: 268.0K shares2025-Q3: 225.1K shares2025-Q4: 68.3K shares2026-Q1: 65.8K shares2026-Q2: 39.3K shares
$164.88(+615.75%)
2026-06-30
JAZZ
JAZZ PHARMACEUTICALS PLC
3.36%160.8K$38.7M
-9.75%(-17.38K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 50.5K shares2026-Q1: 178.1K shares2026-Q2: 160.8K shares
$168.09(+45.73%)
2026-06-30
HUM
HUMANA INC
3.25%94.4K$37.5Mnew2025-Q2: 109.5K shares2025-Q3: 3.6K shares2025-Q4: 0 shares2026-Q1: 0 shares2026-Q2: 94.4K shares
$282.69(+37.62%)
2026-06-30
UNH
UNITEDHEALTH GROUP INC
3.19%88.3K$36.7M
+52.10%(+30.24K)
2025-Q2: 34.6K shares2025-Q3: 0 shares2025-Q4: 50.5K shares2026-Q1: 58.0K shares2026-Q2: 88.3K shares
$371.69(+8.08%)
2026-06-30
NBIX
NEUROCRINE BIOSCIENCES INC
3.12%213.4K$36.0M
-1.05%(-2.27K)
2025-Q2: 12.8K shares2025-Q3: 57.2K shares2025-Q4: 163.2K shares2026-Q1: 215.7K shares2026-Q2: 213.4K shares
$137.49(+11.08%)
2026-06-30
INBX
INHIBRX BIOSCIENCES INC
2.54%308.4K$29.2M
+0.97%(+2.95K)
2025-Q2: 244.3K shares2025-Q3: 239.6K shares2025-Q4: 265.5K shares2026-Q1: 305.4K shares2026-Q2: 308.4K shares
$28.74(+207.47%)
2026-06-30
UTHR
UNITED THERAPEUTICS CORP DEL
2.35%50.0K$27.1M
+25.59%(+10.19K)
2025-Q2: 36.4K shares2025-Q3: 95.7K shares2025-Q4: 67.7K shares2026-Q1: 39.8K shares2026-Q2: 50.0K shares
$397.14(+25.83%)
2026-06-30
RVMD
REVOLUTION MEDICINES INC
2.33%143.2K$26.8M
+1.74%(+2.45K)
2025-Q2: 0 shares2025-Q3: 331.1K shares2025-Q4: 151.5K shares2026-Q1: 140.8K shares2026-Q2: 143.2K shares
$43.43(+369.09%)
2026-06-30
ICLR
ICON PUB LTD CO
2.06%136.5K$23.7M
+137.36%(+78.98K)
2025-Q2: 88.2K shares2025-Q3: 133.7K shares2025-Q4: 115.3K shares2026-Q1: 57.5K shares2026-Q2: 136.5K shares
$157.18(+3.80%)
2026-06-30

About Pfm Health Sciences LPโ€™s portfolio

Pfm Health Sciences LP reports $1.17B in US-listed equity holdings across 96 positions in its most recent 13F filing. Its largest disclosed positions are AXSM (4.7%), LLY (4.1%) and JAZZ (3.4%). The top 20 holdings account for 47.53% of reported assets. Its disclosed equity book has returned +51.98% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
AXSM โ€” 5.9% ($53.75M)LLY โ€” 5.2% ($47.09M)JAZZ โ€” 4.3% ($38.74M)HUM โ€” 4.1% ($37.49M)UNH โ€” 4.0% ($36.69M)NBIX โ€” 4.0% ($35.97M)INBX โ€” 3.2% ($29.22M)UTHR โ€” 3.0% ($27.09M)RVMD โ€” 2.9% ($26.82M)ICLR โ€” 2.6% ($23.71M)Other โ€” 60.8% ($552.96M)
39%in top 10
  • AXSM5.9%
  • LLY5.2%
  • JAZZ4.3%
  • HUM4.1%
  • UNH4.0%
  • NBIX4.0%
  • INBX3.2%
  • UTHR3.0%
  • RVMD2.9%
  • ICLR2.6%
  • Other60.8%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
9
HUMHUMANA INC3.3%
MTDMETTLER TOLEDO INTERNATIONAL1.5%
MRKMERCK & CO INC1.4%
CYTKCYTOKINETICS INC1.4%
+5 opened
Added to
19
ICLRICON PUB LTD CO+137.4%
UNHUNITEDHEALTH GROUP INC+52.1%
SYKSTRYKER CORPORATION+157.9%
WATWATERS CORP+50.5%
+15 more
Trimmed
22
THCTENET HEALTHCARE CORP-68.2%
LLYELI LILLY & CO-40.3%
PENPENUMBRA INC-56.9%
AXSMAXSOME THERAPEUTICS INC.-16.9%
+18 more

Unlock alerts, watchlists & AI chat

Sign up free to track Pfm Health Sciences LP, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Pfm Health Sciences LPโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1442756). View Pfm Health Sciences LPโ€™s 13F filings on SEC

More 13F analyses

View all